Company Filing History:
Years Active: 2024
Title: Ausrine Nestarenkaite: Innovator in Tumor-Stroma Interface Detection
Introduction
Ausrine Nestarenkaite is a prominent inventor based in Vilnius, Lithuania. She has made significant contributions to the field of cancer research through her innovative methods in tumor-stroma interface detection. Her work aims to enhance the assessment of anti-tumor responses, ultimately improving patient outcomes.
Latest Patents
Ausrine holds a patent titled "Automated Tumour-Stroma interface zone detection for anti-tumour response assessment by immunogradient indicators." This groundbreaking method involves automatically sampling the tumor/stroma interface zone from microscopy image analysis data. The process begins by delineating the tumor edge using explicit rules in grid-subsampled tissue areas. Subsequently, the interface zone of controlled width is sampled and ranked by the distance from the edge to compute tumor-infiltrating lymphocyte (TIL) density profiles across the interface zone. From this data, a set of novel Immunogradient indicators is computed to reflect TIL 'gravitation' towards the tumor. The method has been applied to CD8 immunohistochemistry images of surgically excised breast and colorectal cancers, demonstrating strong prognostic value that outperforms existing methods.
Career Highlights
Ausrine is affiliated with Vilnius University, where she continues her research and development in the field of immunology and cancer treatment. Her innovative approach has garnered attention in the scientific community, contributing to advancements in understanding tumor behavior and immune response.
Collaborations
Ausrine has collaborated with notable colleagues, including Arvydas Laurinavicius and Allan Rasmusson. Their combined expertise has furthered the research and application of her patented methods.
Conclusion
Ausrine Nestarenkaite's contributions to tumor-stroma interface detection represent a significant advancement in cancer research. Her innovative methods have the potential to improve patient survival rates and enhance the understanding of tumor-immune interactions.